Grape seed supplement shows promise in lowering jaundice bilirubin
NCT ID NCT07575789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether taking grape seed powder along with vitamin C could lower bilirubin levels in people with jaundice caused by liver issues. Twenty-four adults with high bilirubin and other liver markers took the supplement or standard care. Results showed a significant drop in bilirubin for the supplement group, suggesting it may help ease jaundice symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- grape seed powder and vitamin C supplement
- What this could lead to
- If it works, this could offer a simple dietary supplement to help reduce jaundice symptoms by lowering bilirubin levels.
- What could go wrong
- This is a very small, completed study with only 24 participants. The results may not apply to everyone, and the supplement is not a treatment for the underlying liver disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
24 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Apr 2023
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Both men and women * Participants between the ages of 20-40 years will be included * Patients having signs and symptoms of acquired hepatic jaundice * Patients having high serum bilirubin, albumin, ALT, AST, ALP levels * The patient having ALT level more than 10-50 U/L were included * The participants having AST level above than 0-40 IU/L were included in this study * Patients having ALP level more than 30 - 130 U/L were included in this research study * Patients having level of bilirubin above than 0 - 21 μmol/L were included in this investigation * Participants having the range of albumin more than 30-50 g/L were included in this research * Participants those were underweighted were included Exclusion Criteria: * Patients who already taking any supplement or medication * Participants taking any anti-inflammatory medications * People who were suffering from any other disease * Patients who have any known allergies * Non willing patients * Lactating women * Pregnant women * Smokers
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acquired hepatic jaundice are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Lahore
Lahore, Punjab Province, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.